Ozurdex Implant In Non Infectious Posterior Uveitis

Ozurdex Implant in Non Infectious Posterior Uveitis

PRESENTING AUTHOR : Dr. UMESH BHAMMARKAR CO –AUTHOR: Dr. DEEPTI MEHTA

Dr. DIVYA NATARAJAN

INSTITUTE: LIONS CLUB OF HYDERABAD SADHURAM EYE HOSPITAL HYDERABAD

• Introduction:

• Posterior Uveitis is a severe site threatening diseases leading to blinding complications

• Ozurdex 0.7 mg slow sustained release biodegradable intravitreal implant is effective in non infectious posterior uveitis.

• Material and Methods:• Retrospective study of 3 eyes with noninfectious

Uveitic macular edema treated with Ozurdex implant with at least 12 months follow-up time.

• Macular edema was diagnosed by clinical examination, Fluorescein angiography and cirrus optical coherence tomography.

• Patients’ data were collected and included details of uveitis, ocular inflammation, best corrected visual acuity (BCVA) and OCT at baseline and each visit during follow-up.

• Number of injections and potential complications were recorded.

• Results: • 3 eyes (2patients) were included with

posterior uveitis.• Mean follow-up time was 16 months.• All three eyes of two patients showed

decrease inflammatory activity, visual gain (6 weeks follow up) and decreased central retinal thickness (6 months follow up).

• No recurrence or adverse side effects noted within Six months duration.

Sex, Age

Diagnosis BCVA FFA OCT No. of Ozurd

ex

Follow-up

Final BCV

A

M, 30

Posterior Uveitis

6/36 Parafoveal Leak

CME 1 1, 3, 6, Months

6 /12

F, 42

B/L Idiopathic Posterior Uveitis

6/24 Parafoveal Leak

CME 1 1, 3, 6 months

6/9

F, 42

B/L Idiopathic Posterior Uveitis

6/18 Parafoveal Leak

CME 1 1, 3, 6 months

6/9

Graph 1 – BCVA

Graph 2 – Central Retinal Thickness

OCT Before Ozurdex OCT After Ozurdex

1, Left Eye

2, Right Eye

2, Left Eye

Conclusion:• Treatment of Non – Infectious posterior Uveitis

with single dose of Dexamethasone implant proved to be efficacious in treatment of Intra Ocular inflammation with its benefit sustained over a period of 6 months.

• Patients are still under follow-up and if recurrence occurs, will plan for second dose of Ozurdex.

• Further prospective studies are needed to determine efficacy, duration of effect and side effects.

TAKE HOME MESSAGEPosterior Uveitis is a severe site

threatening diseases leading to blinding complications

Ozurdex 0.7 mg slow sustained release biodegradable intravitreal implant is effective in non infectious posterior uveitis.

Both FFA and OCT scan are helpful in diagnosis and monitoring the response to treatment.